Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and Rituximab in Mantle Cell Lymphoma (Phase II, Korea)
KCT0007647Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib and rituximab in mantle cell lymphoma (MCL), sponsored by AstraZeneca. Started Oct 2022; status: active, not recruiting.
02
Drugs
acalabrutinibrituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on KCT0007647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007647.